Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 7, Pages 721-735Publisher
SPRINGER
DOI: 10.1007/s00262-014-1549-4
Keywords
Tryptophan catabolism; Immunometabolism; Immune escape; Immune surveillance; Immunoediting; Cancer-associated inflammation
Categories
Funding
- NIH, Department of Defense Breast and Lung Cancer Research Programs
- Susan G. Komen for the Cure
- W.W. Smith Trust
- NewLink Genetics Corporation
- Sharpe-Strumia Foundation
- Dan Green Foundation
- Lankenau Medical Center Foundation
- Main Line Health System
- US Department of Defense Breast Cancer Research Program
Ask authors/readers for more resources
Genetic and pharmacological studies of indoleamine 2,3-dioxygenase (IDO) have established this tryptophan catabolic enzyme as a central driver of malignant development and progression. IDO acts in tumor, stromal and immune cells to support pathogenic inflammatory processes that engender immune tolerance to tumor antigens. The multifaceted effects of IDO activation in cancer include the suppression of T and NK cells, the generation and activation of T regulatory cells and myeloid-derived suppressor cells, and the promotion of tumor angiogenesis. Mechanistic investigations have defined the aryl hydrocarbon receptor, the master metabolic regulator mTORC1 and the stress kinase Gcn2 as key effector signaling elements for IDO, which also exerts a non-catalytic role in TGF-beta signaling. Small-molecule inhibitors of IDO exhibit anticancer activity and cooperate with immunotherapy, radiotherapy or chemotherapy to trigger rapid regression of aggressive tumors otherwise resistant to treatment. Notably, the dramatic antitumor activity of certain targeted therapeutics such as imatinib (Gleevec) in gastrointestinal stromal tumors has been traced in part to IDO downregulation. Further, antitumor responses to immune checkpoint inhibitors can be heightened safely by a clinical lead inhibitor of the IDO pathway that relieves IDO-mediated suppression of mTORC1 in T cells. In this personal perspective on IDO as a nodal mediator of pathogenic inflammation and immune escape in cancer, we provide a conceptual foundation for the clinical development of IDO inhibitors as a novel class of immunomodulators with broad application in the treatment of advanced human cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available